Download the presentation here: PDF

Now We Have a Patch and a Gel
Voltaren Gel (diclofenac), Endo
• In March 2008, Endo announced the acquisition of US marketing rights to
Novartis’ Voltaren Gel, a 1% topical diclofenac (NSAID) gel. Voltaren Gel
was approved by the FDA in October 2007, but was never launched by
Novartis.
• May offer advantages over Flector
– Labeled for use in chronic osteoarthritis pain (Flector carries an acute
use indication)
– Gel formulation allows for use on joints (although 4x/day vs. 1-2)
– Priced at a significant discount (~60%)
SG Cowen Therapeutic Categories Outlook March 2008; Company press release
33
© Defined Health, 2009
Pain Insight Briefing